Shots:

• The ongoing P-III (ADAPT+) 3yr. extension study evaluates Vyvgart in adults patients with gMG. Additionally, 106 AChR-Ab+ & 33 AChR-Ab– received 1 dose of Vyvgart
• The results showed that the long-term treatment with Vyvgart provides a consistent & clinical improvement on MG-ADL & QMG scales that remains consistent over multiple treatment cycles, 54.6% received ≤5.5 treatment cycles/yr. in patients who completed 1yr. of treatment at the time of interim analysis, well-tolerated with a consistent safety profile to the (ADAPT) trial
• Vyvgart is a human IgG1 Ab fragment that binds to FcRN resulting in the reduction of circulating IgG auto Abs. The therapy has been approved in the US & Japan for gMG

Ref: Globe Newswire | Image: Argenx